Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Kabi Awaits Biosimilar Tocilizumab Boost, Upgrades 2024 Guidance
Fresenius Kabi enjoyed a good start to 2024, boosted by the recent US launch of its biosimilar tocilizumab product and a key licensing agreement signed with Teva – factors that have allowed the German generics and biosimilars giant to boost its financial guidance for 2024.
Ozempic, Inhalers, In The Crosshairs As FTC Goes After Hundreds More ‘Junk Patents’
The US Federal Trade Commission is not resting on its laurels after seeing some success in its initial challenge to what it deems improper or irrelevant US patents that may be strangling cheaper generic competition.
Who’s Hired? Teva Brings New Legal Head Onboard
Generics Bulletin reports on some of the most noteworthy and important appointments affecting the global generics and biosimilar industries.
What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most noteworthy and anticipated events for May 2024.
Hikma Strikes AG Nucynta Agreement As Clock Ticks On Opioid’s IP Life
Hikma will look to guarantee US generic competition to the powerful opioid brand Nucynta, albeit in the form of an authorized generic, as questions swirl over the appetite of at least one ANDA filer to compete on an equal footing, per the terms of a patent-litigation settlement deal.
Vanda Comes Up Empty Handed As US Supreme Court Denies Hetlioz Appeal
Vanda looks likely to have to face up to unimpeded US generic competition to its core Hetlioz brand, after a further denial in its litigation against ANDA sponsors Teva and Apotex.